14 Mar 2001
Several new multiple sclerosis treatments will be launched over the next seven years. Immunosuppressants will be first to hit the market and will take $210 million worth of sales in 2001, growing to $370 million by 2007. Monoclonal antibodies will have the largest market share, estimated to be worth $616 million in 2007 after only two years of launch. These drugs pose a threat to the current dominance of the interferon class.
* Marketed products will have a value of over $3 billion by 2007
* Potassium channel blockers will hit the market in 2006 with sales of $185 million, growing to $243 million the next year
* Other treatments introduced in 2006 will have a combined value of
$296 in their initial year and $390 in 2007
© Copyright 2003, DataMonitor